Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | BCL9 | O00512 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754617 | 0.78 | SMN1; SMN2 (0.46) | L3MBTL1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4753078 | 0.77 | L3MBTL1 (0.43) | L3MBTL1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4971079 | 0.76 | L3MBTL1 (0.41) | L3MBTL1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4971085 | 0.76 | L3MBTL1 (0.41) | L3MBTL1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL29369577 | 0.73 | GAA (0.58) | L3MBTL1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL26728271 | 0.73 | GAA (0.51) | L3MBTL1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL10674760 | 0.72 | GAA (0.56) | GAAKMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3617574 | 0.71 | NAAA (0.45) | L3MBTL1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1864730 | 0.71 | MGLL (0.44) | L3MBTL1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1864733 | 0.71 | MGLL (0.44) | L3MBTL1GAAKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184805-A1 | RENIN INHIBITORS | ACE, REN, ACE2 | L3MBTL1 4449/4885GAA 44/4885KMT2A 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.